Investors

Investors

Corporate Profile

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – December 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Jan. 6, 2017-- Regulatory News : Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website :
View HTML
Toggle Summary ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium
LYON, France --(BUSINESS WIRE)--Jan. 17, 2017-- Regulatory News : ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs
View HTML
Toggle Summary ERYTECH to Hold Business Update and 2016 Financial Results Conference Call on March 3rd, 2017
LYON, France --(BUSINESS WIRE)--Feb. 28, 2017-- Regulatory News : ERYTECH (Paris:ERYP) (ADR:EYRYY) :, the clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for Full Year 2016
Conference call and webcast on Friday, March 3rd at 15:00 pm CET / 09:00 am EST Activities for resubmission of European Marketing Authorization Application (MAA) for eryaspase (GRASPA) in relapsed and refractory acute lymphoblastic leukemia (ALL)ongoing after withdrawal in November 2016 ;
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Sep 9 - Sep 10, 2019

Morgan Stanley Global Healthcare Unplugged, New York

Summary Toggle Sep 17, 2019

Business Update and Financial Highlights for the 2nd quarter and first-half of 2019

Summary Toggle Sep 18, 2019 at 8:30 AM EDT

Erytech Pharma Second Quarter 2019 Conference Call and Webcast

RECEIVE E-MAIL ALERTS

Copyright West LLC. Minimum 15 minutes delayed.

Top